HPV+ Recurrent/Metastatic Head and Neck Cancer- Pipeline Insight, 2025
Description
DelveInsight’s, “HPV+ Recurrent/Metastatic Head and Neck Cancer- Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
HPV+ Recurrent/Metastatic Head and Neck Cancer: Overview
Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box). These cancers are referred to as squamous cell carcinomas of the head and neck. Head and neck cancers can also begin in the salivary glands, sinuses, or muscles or nerves in the head and neck, but these types of cancer are much less common than squamous cell carcinomas. Head and neck cancer symptoms may include a lump in the neck or a sore in the mouth or the throat that does not heal and may be painful, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. These symptoms may also be caused by other, less serious conditions. It is important to check with a doctor or dentist about any of these symptoms. Infection with high-risk human papillomaviruses (HPVs) has recently been implicated in the pathogenesis of HNSCCs. It is now widely accepted that high-risk HPV is a cause of almost all cervical cancers as well as some forms of HNSCCs. HPV-related HNSCCs are increasing. HPV-related HNSCCs and HPV-unrelated HNSCCs differ with respect to the molecular mechanisms underlying their oncogenic processes. HPV-related HNSCCs are known to have a better prognosis response to treatment as compared with HPV-unrelated HNSCCs. Therefore, in recent years, it has been required to accurately discriminate between HPV-related and HPV-unrelated HNSCCs. To diagnose the HPV-related HNSCCs, various methods including P16 immunohistochemistry, FISH, and genetic analyses of the HPV gene from histopathological and liquid biopsy specimens have been employed. HPV is a DNA virus that infects the skin and mucous membranes. More than 100 types of HPV have been classified to date. Additionally, at least 12% of oropharyngeal cancer, 3% of oral cancer, and 30–60% of pharyngeal carcinoma cases are caused by HPV infection. In general, HPV-positive oropharyngeal carcinoma is highly susceptible to radiation and anticancer drugs and has a better prognosis compared with HPV-negative cancer. People who are at risk of head and neck cancers―particularly those who use tobacco―should talk with their doctor about ways to stop using tobacco to reduce their risk. Avoiding oral HPV infection can reduce the risk of HPV-associated head and neck cancers. In June 2020, the Food and Drug Administration granted accelerated approval of the HPV vaccine Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58 in persons aged 9 through 45 years. Head and neck cancer treatment can include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, or a combination of treatments. The treatment plan for an individual patient depends on a number of factors, including the location of the tumor, the stage of the cancer, and the person’s age and general health.
“HPV+ Recurrent/Metastatic Head and Neck Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline landscape is provided which includes the disease overview and HPV+ Recurrent/Metastatic Head and Neck Cancer treatment guidelines. The assessment part of the report embraces, in depth HPV+ Recurrent/Metastatic Head and Neck Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HPV+ Recurrent/Metastatic Head and Neck Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the HPV+ Recurrent/Metastatic Head and Neck Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HPV+ Recurrent/Metastatic Head and Neck Cancer Emerging Drugs
Further product details are provided in the report……..
HPV+ Recurrent/Metastatic Head and Neck Cancer: Therapeutic Assessment
This segment of the report provides insights about the different HPV+ Recurrent/Metastatic Head and Neck Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
HPV+ Recurrent/Metastatic Head and Neck Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HPV+ Recurrent/Metastatic Head and Neck Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HPV+ Recurrent/Metastatic Head and Neck Cancer drugs.
HPV+ Recurrent/Metastatic Head and Neck Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
HPV+ Recurrent/Metastatic Head and Neck Cancer: Overview
Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box). These cancers are referred to as squamous cell carcinomas of the head and neck. Head and neck cancers can also begin in the salivary glands, sinuses, or muscles or nerves in the head and neck, but these types of cancer are much less common than squamous cell carcinomas. Head and neck cancer symptoms may include a lump in the neck or a sore in the mouth or the throat that does not heal and may be painful, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. These symptoms may also be caused by other, less serious conditions. It is important to check with a doctor or dentist about any of these symptoms. Infection with high-risk human papillomaviruses (HPVs) has recently been implicated in the pathogenesis of HNSCCs. It is now widely accepted that high-risk HPV is a cause of almost all cervical cancers as well as some forms of HNSCCs. HPV-related HNSCCs are increasing. HPV-related HNSCCs and HPV-unrelated HNSCCs differ with respect to the molecular mechanisms underlying their oncogenic processes. HPV-related HNSCCs are known to have a better prognosis response to treatment as compared with HPV-unrelated HNSCCs. Therefore, in recent years, it has been required to accurately discriminate between HPV-related and HPV-unrelated HNSCCs. To diagnose the HPV-related HNSCCs, various methods including P16 immunohistochemistry, FISH, and genetic analyses of the HPV gene from histopathological and liquid biopsy specimens have been employed. HPV is a DNA virus that infects the skin and mucous membranes. More than 100 types of HPV have been classified to date. Additionally, at least 12% of oropharyngeal cancer, 3% of oral cancer, and 30–60% of pharyngeal carcinoma cases are caused by HPV infection. In general, HPV-positive oropharyngeal carcinoma is highly susceptible to radiation and anticancer drugs and has a better prognosis compared with HPV-negative cancer. People who are at risk of head and neck cancers―particularly those who use tobacco―should talk with their doctor about ways to stop using tobacco to reduce their risk. Avoiding oral HPV infection can reduce the risk of HPV-associated head and neck cancers. In June 2020, the Food and Drug Administration granted accelerated approval of the HPV vaccine Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58 in persons aged 9 through 45 years. Head and neck cancer treatment can include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, or a combination of treatments. The treatment plan for an individual patient depends on a number of factors, including the location of the tumor, the stage of the cancer, and the person’s age and general health.
“HPV+ Recurrent/Metastatic Head and Neck Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline landscape is provided which includes the disease overview and HPV+ Recurrent/Metastatic Head and Neck Cancer treatment guidelines. The assessment part of the report embraces, in depth HPV+ Recurrent/Metastatic Head and Neck Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HPV+ Recurrent/Metastatic Head and Neck Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence HPV+ Recurrent/Metastatic Head and Neck Cancer R&D. The therapies under development are focused on novel approaches to treat/improve HPV+ Recurrent/Metastatic Head and Neck Cancer.
This segment of the HPV+ Recurrent/Metastatic Head and Neck Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HPV+ Recurrent/Metastatic Head and Neck Cancer Emerging Drugs
- CUE 101: Cue Biopharma
- BNT 113: BioNTech
Further product details are provided in the report……..
HPV+ Recurrent/Metastatic Head and Neck Cancer: Therapeutic Assessment
This segment of the report provides insights about the different HPV+ Recurrent/Metastatic Head and Neck Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in HPV+ Recurrent/Metastatic Head and Neck Cancer
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
HPV+ Recurrent/Metastatic Head and Neck Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HPV+ Recurrent/Metastatic Head and Neck Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HPV+ Recurrent/Metastatic Head and Neck Cancer drugs.
HPV+ Recurrent/Metastatic Head and Neck Cancer Report Insights
- HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing HPV+ Recurrent/Metastatic Head and Neck Cancer drugs?
- How many HPV+ Recurrent/Metastatic Head and Neck Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HPV+ Recurrent/Metastatic Head and Neck Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HPV+ Recurrent/Metastatic Head and Neck Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for HPV+ Recurrent/Metastatic Head and Neck Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- BioNTech
- Cue Biopharma
- Hookipa Pharma
- CUE 101
- BNT 113
- HB 201
Table of Contents
60 Pages
- Introduction
- Executive Summary
- HPV+ Recurrent/Metastatic Head and Neck Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- HPV+ Recurrent/Metastatic Head and Neck Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Pre-Registration)
- Comparative Analysis
- Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Last Stage Products (Phase III)
- Comparative Analysis
- Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- BNT 113: BioNTech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- HPV+ Recurrent/Metastatic Head and Neck Cancer Key Companies
- HPV+ Recurrent/Metastatic Head and Neck Cancer Key Products
- HPV+ Recurrent/Metastatic Head and Neck Cancer - Unmet Needs
- HPV+ Recurrent/Metastatic Head and Neck Cancer - Market Drivers and Barriers
- HPV+ Recurrent/Metastatic Head and Neck Cancer - Future Perspectives and Conclusion
- HPV+ Recurrent/Metastatic Head and Neck Cancer Analyst Views
- HPV+ Recurrent/Metastatic Head and Neck Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
